{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:30:39Z","timestamp":1791347439193,"version":"4.3.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41375-025-02754-9","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T07:30:56Z","timestamp":1760340656000},"page":"2862-2865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-9393","authenticated-orcid":false,"given":"Rachel B.","family":"Salit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-0850","authenticated-orcid":false,"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2754_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"2754_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"2754_CR3","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395\u20138.","journal-title":"Blood"},{"key":"2754_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa2408941","volume":"392","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Luck C, et al. Clearance of driver mutations after transplantation for myelofibrosis. N Engl J Med. 2025;392:150\u201360.","journal-title":"N Engl J Med"},{"key":"2754_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3324\/haematol.2012.076901","volume":"98","author":"T Lange","year":"2013","unstructured":"Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jakel N, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98:722\u20138.","journal-title":"Haematologica"},{"key":"2754_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/bjh.20003","volume":"206","author":"R Nedumannil","year":"2025","unstructured":"Nedumannil R, Karmi T, Blombery P, Szer J, Ritchie DS, Chee LCY. Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis. Br J Haematol. 2025;206:1160\u20134.","journal-title":"Br J Haematol"},{"key":"2754_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1205387","volume":"13","author":"S Jungius","year":"2023","unstructured":"Jungius S, Adam FC, Grosheintz K, Medinger M, Buser A, Passweg JR, et al. Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes. Front Oncol. 2023;13:1205387.","journal-title":"Front Oncol"},{"key":"2754_CR8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/bmt.2016.98","volume":"51","author":"H Alchalby","year":"2016","unstructured":"Alchalby H, Yunus DR, Zabelina T, Ayuk F, Kroger N. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transpl. 2016;51:1223\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2754_CR9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/bmt.2017.157","volume":"52","author":"C Wolschke","year":"2017","unstructured":"Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, et al. Impact of molecular residual disease post allografting in myelofibrosis patients. Bone Marrow Transpl. 2017;52:1526\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2754_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0302-9","volume":"10","author":"T Jain","year":"2020","unstructured":"Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, et al. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020;10:36.","journal-title":"Blood Cancer J"},{"key":"2754_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","volume":"59","author":"A Sureda","year":"2024","unstructured":"Sureda A, Carpenter PA, Bacigalupo A, Bhatt VR, de la Fuente J, Ho A, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transpl. 2024;59:832\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2754_CR12","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","volume":"35","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021;35:2445\u201359.","journal-title":"Leukemia"},{"key":"2754_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","volume":"20","author":"N Kroger","year":"2014","unstructured":"Kroger N, Zabelina T, Alchalby H, Stubig T, Wolschke C, Ayuk F, et al. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transpl. 2014;20:812\u20135.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2754_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/ajcp\/aqad129","volume":"161","author":"J Wong","year":"2024","unstructured":"Wong J, Jackson R, Chen L, Song J, Pillai R, Afkhami M, et al. Determination of age-dependent bone marrow normocellularity. Am J Clin Pathol. 2024;161:170\u20136.","journal-title":"Am J Clin Pathol"},{"key":"2754_CR15","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.bbmt.2020.07.013","volume":"26","author":"HJ Deeg","year":"2020","unstructured":"Deeg HJ, Salit RB, Monahan T, Schoch G, McFarland C, Scott BL, et al. Early Mixed lymphoid donor\/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis. Biol Blood Marrow Transpl. 2020;26:2197\u2013203.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02754-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02754-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02754-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:10:44Z","timestamp":1763629844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02754-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2754"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02754-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}